西酞普兰治疗躯体形式障碍的临床研究

A Clinical Study of Cipramil in Somatization Disorders

目的探讨对躯体形式障碍较理想的药物。方法采用入院顺序分层随机法,将80例躯体形式障碍患者平均分为研究组(西酞普兰)和对照组(阿米替林)。在治疗前,治疗后1、2、4、8周末分别用症状自评量表(SCL-90)和副反应量表(TESS)评定疗效和副作用。结果治疗1周时研究组SCL-90总分、躯体化、抑郁、焦虑因子分比治疗前明显降低,且治疗因子分显著低于对照组,治疗后1、2、4、8周末TESS评分研究组均低于对照组,有显著性差异。结论西酞普兰治疗躯体形式障碍疗效好,起效快,副作用小。

Objective To explore the ideal drug to treat thesomatization disorders. Methods 80 somatization disorder patients were divided into study group（Cipramil） and control group（Amitriptyline）. Effects and side effects were assessed with SCL--90 and TESS respectively before and after 1,2,4 and 8 weekends treatment. Results Compared with before treatment the total scores of SCL-90,the scores of somatization, depression and anxiety factor were significantly decreased at 1-weekend treatment with study group, and the score of treatment factors was significantly lower than that of control group, The TESS scores of study group were lower than that of control group after 1,2,4 and 8 weekend treatment and the scorese of post-treatment were lower than that of pretreatment, so there were significant difference between those respectively. Coaclusion Cipramil take good effect more quickly and produce fewer side effects in somatoform disorders.